The novel treatment of the medication represents a major development in the management of type 2 diabetes. Unlike existing medications, tirzepatide affects two pathways – glucagon-like peptide-1 (GLP-1) and GIP – https://tirzepatide-peptide251684.atualblog.com/48720832/tirzepatide-peptide-a-new-frontier-in-diabetes-treatment